BACKGROUND/AIMS: To compare non-invasive biological liver fibrosis scores, as alternatives to liver biopsy, in HIV/HCV co-infected patients. METHODS: Two hundred and seventy-two HIV/HCV patients, nai ve for HCV treatment, underwent liver biopsy [197 (72%) men, 39.9 years, fibrosis stage (Metavir) F1 (25%), F2 (40%), F3 (25%), F4 (10%), median CD4 486/mm(3) and median HIV viral load 3.5log. Fibrotest (FT), Hepascore (HS), Fibrometer (FM), SHASTA, APRI, Forns index, and Fib-4 were tested in order to differentiate patients with mild to moderate fibrosis (F2) and those with advanced fibrosis (F3). The AUROC and the rate of well-classified patients were compared to liver biopsy. RESULTS: FT, HS, and FM were able to stage liver fibrosis in all patients with AUROCs of 0.78, 0.84 and 0.89 for the diagnosis of F2, respectively. The correlation coefficient indexes were 0.37, 0.46 and 0.48, respectively. The rates of well-classified patients were 62%, 68% and 71%, respectively. Fib-4, APRI and the Forn's index were only able to stage 37-61% of patients and showed lower accuracies. Using a combination of FT, HS and FM did not significantly increase the performance of each test. CONCLUSIONS: In HIV/HCV co-infected patients, Fibrometer, Hepascore and Fibrotest outperformed other non-invasive liver fibrosis biomarkers for the prediction of significant liver fibrosis.
BACKGROUND/AIMS: To compare non-invasive biological liver fibrosis scores, as alternatives to liver biopsy, in HIV/HCV co-infectedpatients. METHODS: Two hundred and seventy-two HIV/HCV patients, nai ve for HCV treatment, underwent liver biopsy [197 (72%) men, 39.9 years, fibrosis stage (Metavir) F1 (25%), F2 (40%), F3 (25%), F4 (10%), median CD4 486/mm(3) and median HIV viral load 3.5log. Fibrotest (FT), Hepascore (HS), Fibrometer (FM), SHASTA, APRI, Forns index, and Fib-4 were tested in order to differentiate patients with mild to moderate fibrosis (F2) and those with advanced fibrosis (F3). The AUROC and the rate of well-classified patients were compared to liver biopsy. RESULTS: FT, HS, and FM were able to stage liver fibrosis in all patients with AUROCs of 0.78, 0.84 and 0.89 for the diagnosis of F2, respectively. The correlation coefficient indexes were 0.37, 0.46 and 0.48, respectively. The rates of well-classified patients were 62%, 68% and 71%, respectively. Fib-4, APRI and the Forn's index were only able to stage 37-61% of patients and showed lower accuracies. Using a combination of FT, HS and FM did not significantly increase the performance of each test. CONCLUSIONS: In HIV/HCV co-infectedpatients, Fibrometer, Hepascore and Fibrotest outperformed other non-invasive liver fibrosis biomarkers for the prediction of significant liver fibrosis.
Authors: Mamta K Jain; Emmanuel Seremba; Rafia Bhore; Doan Dao; Reeti Joshi; Nahid Attar; He-Jun Yuan; William M Lee Journal: AIDS Patient Care STDS Date: 2012-01-12 Impact factor: 5.078
Authors: Salvador Resino; José M Bellón; Cristina Asensio; Dariela Micheloud; Pilar Miralles; Ana Vargas; Pilar Catalán; Juan C López; Emilio Alvarez; Jaime Cosin; Raquel Lorente; María A Muñoz-Fernández; Juan Berenguer Journal: BMC Infect Dis Date: 2010-08-19 Impact factor: 3.090
Authors: Audrey L French; Charlesnika T Evans; Denis M Agniel; Mardge H Cohen; Marion Peters; Alan L Landay; Seema N Desai Journal: J Infect Dis Date: 2013-05-17 Impact factor: 5.226
Authors: Johannes Vermehren; Annika Vermehren; Axel Mueller; Amina Carlebach; Thomas Lutz; Peter Gute; Gaby Knecht; Christoph Sarrazin; Mireen Friedrich-Rust; Nicole Forestier; Thierry Poynard; Stefan Zeuzem; Eva Herrmann; Wolf Peter Hofmann Journal: BMC Gastroenterol Date: 2012-03-27 Impact factor: 3.067
Authors: Klaus Langohr; Arantza Sanvisens; Daniel Fuster; Jordi Tor; Isabel Serra; Celestino Rey-Joly; Inmaculada Rivas; Roberto Muga Journal: Open AIDS J Date: 2008-11-20